Future directions in the pharmacology of anti-cancer agents in children

British Medical Bulletin

Volumn 52, Issue 4, 1996, Pages 844-872

  Pearson, A D J ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; MERCAPTOPURINE; METHOTREXATE; OXAZAPHOSPHORINE DERIVATIVE; PACLITAXEL; PLATINUM COMPLEX; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; THYMIDYLATE SYNTHASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL PROTOCOL; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030444835     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a011587     Document Type: Review

References (95)

1. Grochow LB, Baraldi C, Noe D. Is dose normalisation to weight or body surface area useful in adults? J Natl Cancer Inst 1990; 82: 323-5
2. Boos J, Krumpelmann S, Schulze-Westhoff P, Euttng T. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol 1995; 13: 2954-60
3. Boos J, Werber G, Ahlke E. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996; 32: 1504-50
4. Newell DR, Pearson ADJ, Balmanno K et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 1993; 11: 2314-23
5. Evans WE, Crom WR, Stewart CE et al. Methotrexate systemic clearance influences the probability of relapse in children with standard risk acute lymphocytic leukaemia. Lancet 1984; i: 359-62
6. Lowis SP, Pearson AD, Newell DR. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 1993; 53: 4881-9
7. De Abreu R, Lambooy L, Stet E. Thiopurine induced disturbance of DNA methylation in human malignant cells. Adv Enzyme Regul 1995; 35: 251-63
8. Jodrell DI, Egorin MJ, Canetta RM et al. Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-8
9. Horwich A, Dearnaley DF, Nicholls J et al. Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good prognosis metastatic testicular non-seminomatous germ cell tumors. J Clin Oncol 1991; 9: 62-9
10. Rodman JH, Abromowitch M, Sinkule JA et al. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987; 5: 1007-14
11. Evans WE. Clinical pharmacodynamics of anti-cancer drugs: a basis for extending the concept of dose intensity. Blut 1988; 56: 241-8
12. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation. Semin Oncol 1993; 20 Suppl 4: 18-25
13. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukaemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986; 40: 287-92
14. Lermard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukaemia. J Clin Oncol 1989; 7: 1816-23
15. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994; 343: 118-9
16. Ayash LJ, Wright JE, Tretyakov O. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumour response. J Clin Oncol 1992; 10: 995-1000
17. Evans WE, Crom WR, Abromowitch M et al. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukaemia. N Engl J Med 1986; 341: 471-7
18. Evans WE, Crom WR, Shell MJ et al. Reappraisal of methotrexate clearance as a prognostic factor in childhood acute lymphocytic leukaemia. Proc Am Assoc Cancer Res 1989; 30: 241(957)
19. Pearson ADJ, Amineddine HA, Yule M et al. The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer 1991; 64: 169-73
20. Calvert AH, Newell DR, Gumbrell LA. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56
21. Chatelut E, Canal P, Brunner V. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-80
22. Ploin DY, Tranchand B, Guastalla JP, et al. Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer 1992; 28A: 1311-5
23. Cano JP, Bruno R, Lena N, et al. Dosage predictions in high-dose methotrexate infusions. Part I: Evaluation of the classic test-dose protocol. Cancer Drug Delivery 1985; 2: 271-6
24. Relling MV, Rodman JH, Crom WR. Individualized administration of anti-cancer drugs. Cancer chemotherapy: challenges for the future. Exerpta Medica 1991; 7. Proceedings of the 7th Nagoya International Symposium on Cancer Treatment, Nagoya, Japan
25. English MW, Lowis SP, Peng B. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. Br J Cancer 1996; 73: 776-80
26. Weinshilbourn RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62
27. Lennard L, Lilleyman JS, Van Loon JV, Weinshilbourn RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-9
28. Lennard L, Rees CA, Lilleyman, JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolism and neutropenia. Br J Clin Pharmacol 1993; 16: 359-63
29. McLeod HL, Relling MV, Liu Q. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 85: 1897-902
30. Whitehead VM, Rosenblatt DS, Vuchich MJ, Beaulieu D. Methotrexate polyglutamate synthesis in lymphoblasts from children with acute lymphoblastic leukaemia. Dev Pharmacol Ther 1987; 10: 443-8
31. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukaemia: a pilot prognostic for factor analysis. Blood 1990; 76: 44-9
32. Roberts JJ. The mechanism of action of antitumor platinum coordination compounds. In: Molecular Actions and Targets for Cancer Chemotherapeutic Agents. New York: Academic Press, 1981; 17-43
33. Fram RJ, Woda BA, Wilson JM. Characterization of acquired resistance to cis-diaminedichloroplatinum (II) in BE human colon carcinoma cells. Cancer Res 1990; 50: 72-7
34. Reed E, Yuspa SH, Zwelling LA. Quantitation of cis-diaminedichloroplatinum (II) (cisplatin)-DNA intra-strand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 1986; 77: 545-50
35. Reed E, Ozols RF, Tarone R. Platinum-DNA adducts in leukocyte DNA correlate with disease response in cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987; 84: 5024-8
36. Reed E, Ozols RF, Tarone R. The measurement of cisplatin-DNA levels in testicular cancer patients. Carcinogenesis 1988; 9: 1909-11
37. Reed E, Ostchega Y, Steinberg SM. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990; 50: 2256-60
38. Peng B, Tilby M, English M et al. Cell killing and Pt-DNA adduct formation following cisplatin and carboplatin treatment in neuroblastoma cell lines and neurohlastoma patients. Br J Cancer 1995; 71 Suppl XXIV: 21
39. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHJ. Adducts of the antitumor drug cis-diaminedichloroplatinum (II) with DNA: formation, identification, and quantitation. Biochemistry 1985; 24: 707-13
40. Fichtinger-Schepman AMJ, Dijt FJ, de Jong WH. In vivo cis-diaminedichloroplatinum (II)-DNA adduct formation and removal as measured with immunochemical techniques. Proceeding of the Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Padua, 1987
41. Fichtinger-Schepmann AMJ, van Oosterom AT, Lohman PHM. Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Muta t Res 1987; 190: 59-62
42. Tilby MJ, Johnson C, Knox RJ. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res 1991; 51 123-9
43. Plunkett W, Jacoboni S, Estey E et al. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 1985; 12: 20-30
44. Wiley JS, Tauppin J, Jamieson GP et al. Cytosine arabinoside transport and metabolism in acute leukaemias and T cell lymphoblastic lymphoma. J Clin Invest 1985; 75 632-42
45. Harris AL, Potter C, Bunch C et al. Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol 1979; 8: 219-27
46. Ramilo-Torno L, Avramis V. High dose, conventional dose and biochemically optimal continuous infusion (CI) of cytosine arabinoside (ara-C) in pediatric patients with relapsed leukemia. Proc Am Soc Clin Oncol 1993; 12: 152
47. Plunkett W, Gandhi V. Cellular pharmacodynamics of anti-cancer drugs. Semin Oncol 1993; 20: 50-63
48. Gandhi V, Estey E, Keating M et al. Fludarabine potentiates metabolism of cytarabine in patients with acute mylogenous leukemia during therapy. J Clin Oncol 1993; 11: 116-24
49. Lockhart S, Plunkett W, Jeha S et al. High dose mercaptopurine followed by intermediate dose cytarabine in relapsed acute leukemia. J Clin Oncol 1994; 12: 587-95
50. D'Arpa P, Liu LF. Topoisomerase targeting antitumor drugs. Biochim Biophys Acta 1989; 989: 163-77
51. Austin CA, Sng JH, Patel S et al. Novel HeLa topo II is the topo II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta 1993; 1172: 283-91
52. Patel S, Austin CA, Fisher LM. Development and properties of a human leukemic cell line resistant to the topoisomerase II inhibitor etoposide. Anticancer Drug Des 1990; 5: 149-57
53. Chang TKH, Weber GF, Crespi CL. Differential activation of cyclophosphamide and ifosfamide by cytochromes P4502B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-37
54. Yule SM, Boddy AV, Cole M et al. Cyclophosphamide metabolism in children. Cancer Res 1995; 55: 803-9
55. Yule SM. The Clinical Pharmacology of Cyclophosphamide in Children. PhD Thesis, University of Newcastle upon Tyne, UK, 1996
56. Murray GI, Weaver, RJ, Ewen SWB. Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol 1993; 169: 347-53
57. Chen L, Waxman DJ, Chen D. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996; 56: 1331-40
58. Friedman HS, Colvin OM, Kaufmann SH et al. Cyclophosphamide resistance in medulloblastoma. Cancer Res 1990; 52: 5373-8
59. Horowitz M, Etcubanas E, Christensen M et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anti-cancer drug development. J Clin Oncol 1988; 6: 308-14
60. Vassal G, Morizet J, Bissery MC et al. Activity of the campthothecin analog CPT-11 (irinotecan) against neuroblastoma xenografts. Med Pediatr Oncol 1994; 23: 207
61. Taylor GA. et al. A phase I study of the novel antifolate 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (G3337) given by a 24 hr continuous infusion. Br J Cancer 1994; 69 (Suppl XXIV): 23
62. Donehower R, Grove W, Whitfield L et al. Successful use of pharmacologically guided dose escalation in a phase I trial of CI-598. Proc Am Soc Clin Oncol 1993; 12: 139
63. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9
64. Tubergen D, Pratt C, Stewart C et al. Phase I study of topotecan in children with refractory solid tumours: a Pediatric Oncology Group Study. Proc Am Soc Oncol 1994; 13: 167
65. Newlands ES, Blackridge GRP, Slack JA. Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br J Cancer 1992; 65: 287-91
66. Prendiville J, Crowther D, Thatcher N et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993; 68: 418-24
67. Doz F, Pinkerton R. What is the place of carboplatin in paediatric oncology? Eur J Cancer 1994; 30A: 194-201
68. Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol 1993; 11: 173-90
69. Blaney S, Seibel N, O'Brien M et al. A phase I study of taxotere in pediatric patients. Proc Am Assoc Cancer Res 1994; 35: 211
70. Stevens MFG, Hickman JA, Stone R. Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo[5,1-dd]]-1, 2,3,5-terazin-4(3H)-one on the DNA of mouse L1210 cells. Cancer Res 1984; 44: 1767
71. 6-alkylguanine DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 1993; 67: 1299-302
72. Stevens, MFG, Hickman JA, Langdon SP et al. Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-terazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846-52
73. O'Reilly SM, Newlands ES, Glaser MG. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993; 29A: 940-2
74. Bleehan NM, Newlands ES, Lee SM. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13: 910-3
75. Pearson ADJ, Estlin EJ, Lashford L et al. Phase I study of temozolomide in paediatric patients with advanced cancer. Proc Am Soc Oncol 1996; 15: 1564 p490
76. 6-alkylguanine DNA alkyltransferase with twice daily oral temozolomide (sch 52365) in patients with advanced cancer. Proc Am Soc Clin Oncol 1996; 15: 178
77. 10 propargyl 5,8 dideazafolic acid (CB3717). Cancer Chemother Pharmacol 1985; 14: 265-71
78. Jackman AL, et al. ICI D1694, a quinazoline antifolate TS inhibitor that is a potent inhibitor of L1210 cells in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51: 5579-86
79. Yin MB, et al. Effects of the specific thymidylate synthase inhibitors ICI D1694, LY231514 and AG331 on the fragmentation of mature and nascent DNA. Proc Am Ass Cancer Res 1993; 34: 566-7
80. Bernard J, Bourhis J, de Vathaire F. Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis. Adv Neuroblastoma Res 1994; 4: 111-6
81. Nakagaware A, et al. Inverse correlation between expression of multidrug resistance gene and n-myc oncogene in human neuroblastomas. Cancer Res 1990; 50: 3043-7
82. Pinkerton CR, et al. Reversal of etoposide resistance with verapamil. Med Paediatr Oncol 1992; 20: abstr 269
83. List AF, et al. Phase I/II trial of cyclosporin as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-60
84. Boote DJ, Dennis IF, Twentyman PR. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610-8
85. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-96
86. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-54
87. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 1994; 77: 175-8
88. Redfern CPF, Lovat PE, Malcolm AJ, Pearson ADJ. Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of a cis and all trans retinoic acid. Eur J Cancer 1995; 31A: 486-94
89. Sidell N, Wada R, Han G et al. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer 1995; 60: 507-14
90. Stockhammer G, Manley GT, Johnson R. Inhibition of proliferation and induction of differentiation in medulloblastoma and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 1995; 83: 672-81
91. Chen ZX, Breitman TR. Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 1994; 54: 3494-9
92. Marsoni S, Ungerleider R, Hurson S et al. Tolerance of antineoplastic agents in children and adults. Cancer Treat Rep 1985; 64: 1263-9
93. Pratt C. The conduct of phase I-II clinical trials in children with cancer. Med Pediatr Oncol 1991; 19: 304-9
94. Hurwiz C, Relling M, Weitman S et al. Phase I trials of paclitaxel in children with refractory solid tumours: a Paediatric Oncology Group study. J Clin Oncol 1993; 11: 2324-9
95. Smith M, Adamson P, Balis F et al. Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients. J Clin Oncol 1992; 1666-73